Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. in vitro study
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

In Vitro Study Articles & Analysis

36 news found

CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research

CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research

Based on these properties, PDMS has been used in a wide range of applications such as micropumps, catheter surfaces, dressings and bandages, microvalves, optical systems, in vitro disease studies, implants, microfluidics, and photonics. In addition, PDMS is the most widely used material for the manufacture of microfluidic devices, which are an important ...

ByCD Bioparticles


Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

This critical step in the drug development process refers to the systematic evaluation of the safety of therapeutic drugs through laboratory studies and animals in vitro. Alfa Chemistry has established a drug safety evaluation system that meets international standards, helping clients to shorten the experimental time and reduce the cost as well. ...

ByAlfa Chemistry


BIOtechNOW featured IVS’s participating BIO Innovation Zone

BIOtechNOW featured IVS’s participating BIO Innovation Zone

Our tissues are reproducible, uniform, have long-term consistent and accurate functionality and responsiveness to cardio-active and cardio-toxic substances and will be an ideal in vitro model for the study of acute and chronic toxicity.” Tailored to represent diverse human populations and specific diseased states, our cardiac tissue model can offer an ...

ByInvivoSciences, Inc. (IVS)


Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

This formulation (Bupigel) prolonged bupivacaine release from the formulation in dissolution-like studies in vitro and analgesia in vivo in mouse, rat, and pig models. In this study we assessed Bupigel neurotoxicity on rabbit sciatic nerve using histopathology and electrophysiologic testing. Sciatic nerves of both hind limbs were injected ...

ByVirpax Pharmaceuticals


Beyond Cancer Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

Beyond Cancer Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

” The manuscript published in CCI describes several studies of in-vitro and in-situ tumor ablation utilizing a single intratumoral treatment of UNO with secondary anti-tumor effects. In one study, CT26 tumor-bearing mice were treated with a single 5-minute administration of 50,000 ppm gaseous nitric oxide (gNO) or 20,000 ppm gNO versus ...

ByBeyond Air Inc


Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

” At the meetings, the company presented data from IND-enabling studies demonstrating the safety and pharmacokinetic profile of OLX-07010 in in vitro and in vivo preclinical studies. In multiple animal species, OLX-07010, a novel small molecule inhibitor of tau self-association, demonstrated good oral bioavailability, with no significant ...

ByOligomerix, Inc.


Photodisinfection successfully eradicates pathogens associated with replacement joint infections

Photodisinfection successfully eradicates pathogens associated with replacement joint infections

A research team in Zurich, Switzerland has presented results from an in vitro study showing that photodisinfection achieved >99.99% eradication (4-7 log10 kill) of the key pathogens in biofilms associated with implantable joint infections, with no reported regrowth. ...

ByOndine Biomedical Inc


Ondine’s photodisinfection kills ESKAPE pathogens

Ondine’s photodisinfection kills ESKAPE pathogens

(LON: OBI), this week presented an in vitro study at the World Anti-Microbial Resistance Congress, in Maryland, USA on the effectiveness of its photodisinfection technology against the group of highly infectious and antibiotic-resistant bacteria known as ESKAPE pathogens.[i] ESKAPE pathogens are the most virulent and dangerous pathogens responsible for some of ...

ByOndine Biomedical Inc


Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022

Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022

Presentation highlights: Araris’ anti-Nectin-4 antibody-drug conjugate (ADC) showed superior activity to enfortumabvedotin (Padcev®, EV) in head-to-head in vitro and in vivo studies Araris’ linker technology was used to generate a highly homogenous and pure ADC within 24 hours with enfortumab as the targeting antibody and monomethyl auristatin ...

ByAraris Biotech AG


Biomedical Catalyst Grant Award to Arterius Limited

Biomedical Catalyst Grant Award to Arterius Limited

Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb. ...

ByArterius Limited


Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

“We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and ...

ByMicrobion Corporation


AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Darker pigmentation observed may be a sign of multi-functional cystinosin activity post gene therapy Patients with cystinosis frequently exhibit blond or lighter-colored hair and fair complexion because of reduced levels of melanin in their skin. In vitro studies have demonstrated that cystinosin is located in melanosomes of melanocytes and when functional ...

ByTectonic Therapeutic, Inc.


Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

The newly introduced antigens consist of five of the most common staphylococcus aureus enterotoxins and are ideal for in vitro detection and diagnostic studies. Staphylococcus aureus is a Gram-positive spherical bacterium about 1 µm in diameter that forms clusters. ...

ByCreative Diagnostics


COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared to baseline at six months Persistence of memory B and T cell immune responses at six months post second dose Pronounced SARS-CoV-2-specific T cell response to COVAXIN™ before and ...

ByOcugen, Inc.


Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data from COVAXIN (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data from COVAXIN (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. ...

ByOcugen, Inc.


Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition

The results show the synergistic effect of combining CYNK-101 with daratumumab to drive antibody dependent cellular cytotoxicity activity against CD38+ hematological malignancies in vitro and in vivo. In these studies, CYNK-101 was not susceptible to daratumumab-directed fratricide and did not display on-target, off-tumor cytotoxicity, suggesting CYNK-101 may be ...

ByCelularity Inc.


Fab’entech, winner in an ambitious European programme, has been awarded 9.2 million euros to develop its treatment against Covid-19 and its variants.

Fab’entech, winner in an ambitious European programme, has been awarded 9.2 million euros to develop its treatment against Covid-19 and its variants.

The aim of the EPIC-CROWN-2 project is rapid assessment of the clinical benefits of FABENCOV in a multi-centre Phase II a/b study on 400 patients, conducted in four European countries. Moreover, additional studies conducted in vitro and in vivo will make it possible to optimise the product’s therapeutic indications by documenting its ...

ByFab’entech


ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER

ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study with Letrozole, Palbociclib and Onapristone ER

Extended release Onapristone (Onapristone ER) is a progesterone receptor (PR) antagonist that inhibits hormone-mediated PR activation and stabilizes PR association with compressors, resulting in an antineoplastic effect when applied alone or in combination with antiestrogen therapy to breast cancer cells in vitro (1). Recent preclinical studies further suggest ...

ByContext Therapeutics Inc.


Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data, including the possibility of ...

ByOcugen, Inc.


Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico`s Proprietary End-to-end Artificial Intelligence Platform

Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico`s Proprietary End-to-end Artificial Intelligence Platform

It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease which results in progressive and irreversible decline in lung function. After completing IND-enabling studies, Insilico Medicine has initiated the microdose trial to begin characterizing the pharmacokinetic profile in humans. ...

ByInsilico Medicine

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT